🇺🇸 FDA

P1 · Therapeutic area intelligence

Oncology patent intelligence

Anticancer agents, immuno-oncology, ADC, and oncology patent filings — grants, expirations, and assignee activity.

Patents
1,930

Quick answer

1,930 US pharmaceutical patents in our index match Oncology title keywords (A61K/A61P). Cross-link to related drug therapeutic-area hubs and company patent portfolios for full IP context.

  1. US 11566076

    Anti-CSF1R antibody and anti-PD-1 antibody combination therapy for selected cancers

    Five Prime Therapeutics, Inc. · Granted Tue Jan 31 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11564954

    Tumor-delivered multi-target therapeutics for colon cancer

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Tue Jan 31 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11559583

    Anti-CSF1R antibody and agonistic anti-CD40 antibody combination therapy for cancer

    Five Prime Therapeutics, Inc. · Granted Tue Jan 24 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11560414

    Kits comprising myokines and platinum-based chemotherapeutic agents for treating colorectal cancer

    Northwestern University · Granted Tue Jan 24 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11560356

    Compounds and compositions for the treatment of cancer

    The Regents of the University of California · Granted Tue Jan 24 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11559574

    Whole-cell cancer vaccines and methods for selection thereof

    BriaCell Therapeutics Corp. · Granted Tue Jan 24 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11554140

    Nucleic acid, chimeric antigen receptor expression plasmid, chimeric antigen receptor expressing cell, use thereof, and pharmaceutical composition for treating cancer

    China Medical University Hospital · Granted Tue Jan 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11555057

    Compositions and methods for inhibiting tumor cells by inhibiting the transcription factor ATF5

    The Regents of the University of California · Granted Tue Jan 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11555056

    Methods and materials for treating cancer

    Mayo Foundation for Medical Education and Research and Board of Regents · Granted Tue Jan 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11541077

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Tue Jan 03 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11541045

    Methods of treating cancer with farnesyltransferase inhibitors

    Kura Oncology, Inc. · Granted Tue Jan 03 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11529363

    Methods of treating cancer in pediatric patients

    Takeda Pharmaceutical Company Limited · Granted Tue Dec 20 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11529372

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Tue Dec 20 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11524017

    Method of using substrates of AKR1B1/AKR1B10 as anti-cancer drugs

    Beijing Normal University Hong Kong Baptist University United International College · Granted Tue Dec 13 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11524044

    Strengthening and tumor eliminating traditional Chinese medicine composition, its preparation method and application

    The First Afiliated Hospital of Guangzhou University of Chinese Medicine · Granted Tue Dec 13 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11517592

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Tue Dec 06 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11519007

    Tumor-navigating, self-eradicating, trail-armed salmonella for precision cancer therapy

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Tue Dec 06 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11512141

    Fibrinogen-like protein 2 (FGL2) monoclonal antibodies and their use in cancer detection and treatment

    The Board of Regents of the University of Texas System · Granted Tue Nov 29 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11505574

    Modulation of P53 for the treatment of cancer

    The Regents of the University of California · Granted Tue Nov 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11505604

    Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer

    PRECISION BIOLOGICS, INC. · Granted Tue Nov 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 11505600

    Methods of treating skin cancer by administering a PD-1 inhibitor

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 11497740

    Use of Jumonji C demethylase inhibitors for the treatment and prevention of chemotherapy resistance and radioresistance in cancer

    The Board of Regents of the University of Texas System · Granted Tue Nov 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 11497770

    Compositions and methods for treating cancer with TSLPR-CD19 or TSLPR-CD22 immunotherapy

    The Regents of the University of Colorado · Granted Tue Nov 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 11497781

    Methods of treating bladder cancer by combination therapy comprising the oncolytic adenovirus CG0070 and an immune checkpoint inhibitor

    CG ONCOLOGY, INC. · Granted Tue Nov 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 11497713

    Combination taxoid nanoemulsion with immunotherapy in cancer

    Northwestern University · Granted Tue Nov 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 11498963

    Anti-LILRB antibodies and their use in detecting and treating cancer

    The Board of Regents of the University of Texas System · Granted Tue Nov 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 11484581

    Method to create personalized canine cancer vaccines

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Tue Nov 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 11484511

    Pharmaceutical composition comprising THA as effective ingredient for treatment of prostate cancer

    KOREA UNITED PHARM. INC. · Granted Tue Nov 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 11478500

    Anticancer compositions and methods for making and using them

    The Regents of the University of California · Granted Tue Oct 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 11479611

    HLA-G specific chimeric antigen receptor, nucleic acid, HLA-G specific chimeric antigen receptor expression plasmid, HLA-G specific chimeric antigen receptor expressing cell, use thereof, and pharmaceutical composition for treating cancer

    China Medical University Hospital · Granted Tue Oct 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 11479613

    Methods for treating cancer or modulating T cells or NK cells in a subject by administering cells comprising chimeric transmembrane proteins

    AUTOLUS LIMITED · Granted Tue Oct 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 11479769

    Technique for treating cancer using structurally-reinforced S-TuD

    GeneDesign, Inc. · Granted Tue Oct 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 11479614

    Methods for treating cancer or modulating T cells or NK cells in a subject with cancer by administering cells comprising chimeric cytokine receptors

    AUTOLUS LIMITED · Granted Tue Oct 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 11479774

    Methods of treating cancer harboring hemizygous loss of TP53

    The Board of Regents of the University of Texas System · Granted Tue Oct 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 11471491

    Materials and methods for engineering cells and uses thereof in immuno-oncology

    CRISPR THERAPEUTICS AG · Granted Tue Oct 18 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 11471460

    Autophagy modulators for use in treating cancer

    THE UNITED STATES OF AMERICA, represented by the Secretary, Department of Health and Human Services · Granted Tue Oct 18 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 11472812

    Anti-cancer compounds targeting Ral GTPases and methods of using the same

    The Regents of the University of Colorado, a Body Corporate · Granted Tue Oct 18 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 11464774

    Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors

    Vertex Pharmaceuticals Incorporated · Granted Tue Oct 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 11464784

    Inhibition of aminocylase 3 (AA3) in the treatment of cancer

    The Regents of the University of California · Granted Tue Oct 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 11464801

    Compositions and methods for treating cancer with anti-CD33 immunotherapy

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Oct 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 11458212

    Molecular imaging of cancer cells in vivo

    Arizona Board of Regents on Behalf of the University of Arizona · Granted Tue Oct 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 11458127

    Methods of treating brain tumors using combination therapy

    Agios Pharmaceuticals, Inc. · Granted Tue Oct 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 11458171

    Engineering stem cells for cancer therapy

    China Medical University · Granted Tue Oct 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 11459381

    Antibody and antigen-binding fragment compositions targeting cell surface antigens in tumors and methods of use thereof

    UNIVERSITY OF CONNECTICUT · Granted Tue Oct 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 11458126

    DHODH inhibitor for use in treating hematologic cancers

    PTC THERAPEUTICS, INC. · Granted Tue Oct 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 11453640

    Small molecules for disrupting the super elongation complex and inhibiting transcription elongation for cancer therapy

    Northwestern University · Granted Tue Sep 27 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 11453719

    Compositions and methods for treating cancer with anti-ROR1 immunotherapy

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Sep 27 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 11446332

    Combinatorial cancer immunotherapy

    Senti Biosciences, Inc. · Granted Tue Sep 20 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many Oncology patents are indexed?

1,930 patents match our Oncology classifier (title keywords in USPTO records).

Is this legal or medical advice?

No — patent intelligence is for professional reference. Verify expiration and FTO with qualified patent counsel and primary USPTO records.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.